Manages spasticity. ANDA 213223, held by Alembic. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 213223 (Tizanidine Hydrochloride), held by Alembic, was first approved by FDA on Jan 13, 2020, with 2 approved supplements and 0 published complete response letters.
Tizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 13, 2020 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 6MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Sep 24, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 10, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 13, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters